Blanket Purchase Agreement 36F79719D0283-36E79720A0006
Award Date
1/31/20
Last Date to Order
1/30/25
Federal Agency
National Acquisition Center
Awardee
Lundbeck LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Lundbeck LLC a 5-year Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with a potential value of $124 million. Through this contract vehicle, the VA and other federal agencies can procure Lundbeck's portfolio of medications used to treat neurological conditions prevalent among veterans, including Sabril (vigabatrin) for treatment-resistant seizures, Xenazine (tetrabenazine) for chorea...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA has a ceiling value of $118,500,000 and a period of performance from August 2024 to August 2026, with an option year extending it to August 2027. The BPA is for the procurement of specialized pharmaceutical products, primarily focused on medications for the treatment of rare diseases and pulmonary...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Abbvie US LLC, a for-profit limited liability company subsidiary of the global biopharmaceutical firm Abbvie Inc. The single-award BPA has a ceiling value of $15,000,000 and a period of performance through July 31, 2026. The BPA is for the procurement of the pharmaceutical products DUOPA and VYALEV, which are used to treat Parkinson's disease. As a key federal contractor in the...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...